摘要
目的探讨安罗替尼联合多西他赛二线治疗晚期非小细胞肺癌(NSCLC)的临床效果及安全性。方法选取84例晚期NSCLC患者,按随机数字表法分为2组,各42例。对照组予以多西他赛治疗,观察组加用安罗替尼治疗,持续用药2个周期。比较2组临床疗效、肿瘤标志物水平、生存质量及不良反应。结果观察组疾病控制率高于对照组,差异有统计学意义(P<0.05)。观察组治疗后癌胚抗原(CEA)[(7.15±1.03)μg/L]、血管内皮生长因子(VEGF)[(55.36±5.18)ng/L]、糖类抗原50(CA50)[(10.29±1.29)U/ml]及细胞角质蛋白19片段抗原21-1(CYFRA21-1)水平[(2.04±0.42)ng/ml]低于对照组[(9.28±1.24)μg/L、(64.15±6.27)ng/L、(12.02±2.05)U/ml、(2.58±0.44)ng/ml],有统计学差异(P<0.05)。观察组治疗后生存质量中生理领域评分[(84.76±7.29)分]、心理领域评分[(82.58±7.14)分]、环境领域评分[(88.31±8.25)分]及社会领域评分[(86.65±7.29)分]高于对照组[(75.85±7.15)分、(73.35±6.89)分、(81.64±8.15)分、(80.75±7.05)分],有统计学差异(P<0.05)。2组均无严重不良反应。结论安罗替尼联合多西他赛可增强晚期NSCLC控制效果,降低CEA、VEGF、CA50、CYFRA21-1水平,改善生存质量,且未增加不良反应发生风险。
Objective To investigate the clinical efficacy and safety of erlotinib combined with docetaxel in the treatment of advanced non-small cell lung cancer(NSCLC).Methods 84 patients with advanced NSCLC were selected and divided into 2 groups according to the random number table,42 patients in each group.The control group was treated with docetaxel,and the observation group was treated with arrotinib for 2 cycles.The clinical efficacy,tumor marker level,quality of life and adverse reactions of the 2 groups were compared.Results The disease control rate of the observation group was higher than that of the control group(P<0.05);Carcinoembryonic antigen(CEA)after treatment in the observation group[(7.15±1.03)]μg/L],vascular endothelial growth factor(VEGF)[(55.36±5.18)ng/L],carbohydrate antigen 50(CA50)[(10.29±1.29)U/ml]and cytokeratin 19 fragment antigen 21-1(CYFRA21-1)levels[(2.04±0.42)ng/ml]were lower than those in the control group[(9.28±1.24)μg/L,(64.15±6.27)ng/L,(12.02±2.05)U/ml,(2.58±0.44)ng/ml],with statistical difference(P<0.05);After treatment,the scores of physiological field[(84.76±7.29)points],psychological field[(82.58±7.14)points],environmental field[(88.31±8.25)points]and social field[(86.65±7.29)points]in the observation group were higher than those in the control group[(75.85±7.15)points,(73.35±6.89)points,(81.64±8.15)points,(80.75±7.05)points],with statistical differences(P<0.05);There were no serious adverse reactions in both groups.Conclusion Androtinib combined with docetaxel can enhance the control effect of advanced NSCLC,reduce the levels of CEA,VEGF,CA50,CYFRA21-1,improve the quality of life,and do not increase the risk of adverse reactions.
作者
诸葛雪朋
王保收
张浩业
徐志巧
ZHUGE Xuepeng;WANG Baoshou;ZHANG Haoye(Kaifeng Central Hospital,Kaifeng,475000)
出处
《实用癌症杂志》
2024年第1期87-89,93,共4页
The Practical Journal of Cancer
